Suraksha Diagnostic Limited has formally declared that its promoters and promoter group members have not encumbered any shares held in the company during the financial year ended 31 March 2026. The declaration, submitted on 03 April 2026, was made in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The confirmation was provided by Dr. Somnath Chatterjee on behalf of all promoters, promoter groups, and persons acting in concert (PAC).

The disclosure was addressed to the stock exchanges, including BSE Limited and the National Stock Exchange of India (NSE), with the scrip code 544293 and symbol SURAKSHA. The promoters confirmed that no shares were encumbered directly or indirectly, other than those already disclosed during the specified financial year. This move ensures transparency and adherence to regulatory requirements.

Promoter Group Details

The declaration includes a comprehensive list of promoters and promoter group members, as outlined in Annexure-A. The key promoters include Dr. Somnath Chatterjee, Ritu Mittal, and Satish Kumar Verma, each accompanied by their respective promoter group members. Below is a summary of the promoter structure:

Entities in the Promoter Group

Annexure-B lists 62 entities forming part of the promoter group, including companies like Dneema Overseas Private Limited, Tinni Investments Limited, and Oscar International Limited. The list also includes various LLPs and HUFs, such as Terriific Infracon LLP and Bipul Mittal HUF. These entities are integral to the promoter group structure of Suraksha Diagnostic Limited.

The declaration was signed by Dr. Somnath Chatterjee, Promoter of Suraksha Diagnostic Limited, and copies were sent to the Audit Committee and the Company Secretary & Compliance Officer for record-keeping. This filing underscores the company's commitment to regulatory compliance and transparency in its shareholding patterns.

Suraksha Diagnostic Limited has filed its quarterly compliance certificate with stock exchanges for the quarter ended March 31, 2026. The certificate, issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, was submitted to both BSE Limited and The National Stock Exchange of India Limited on April 06, 2026.

Regulatory Compliance Certificate

The certificate was issued by KFin Technologies Limited, which serves as the Registrar and Share Transfer Agent for Suraksha Diagnostic Limited. KFin Technologies has its registered office at Selenium, Tower B, Plot No- 31 & 32, Financial District, Nanakramguda, Serilingampally, Rangareddi, Hyderabad-500032, Telangana.

Certificate Details

The certificate specifically states that no security certificate was received for dematerialization and/or rematerialization during the quarter ended March 31, 2026. This certification is a mandatory requirement under SEBI regulations for companies to report their share transfer activities through their registrar and transfer agents.

The certificate was signed by Ganesh Chandra Patro, Deputy Vice President at KFin Technologies Limited, and submitted to the exchanges by Mamta Jain, Company Secretary & Compliance Officer of Suraksha Diagnostic Limited.

Regulatory Framework

Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, requires registrar and transfer agents to provide quarterly certificates regarding the processing of security certificates for dematerialization and rematerialization. This ensures transparency in share transfer processes and maintains investor confidence in the securities market.

The filing demonstrates Suraksha Diagnostic Limited's commitment to regulatory compliance and transparent reporting practices. Such regular compliance filings are essential for maintaining good corporate governance standards and meeting stock exchange listing requirements.